BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35897085)

  • 1. 5mC and H3K9me3 of TRAF3IP2 promoter region accelerates the progression of translocation renal cell carcinoma.
    Yang L; Chen Y; Liu N; Lu Y; Li X; Ma W; Gan W; Li D
    Biomark Res; 2022 Jul; 10(1):54. PubMed ID: 35897085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
    Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
    J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CircMET promotes tumor proliferation by enhancing CDKN2A mRNA decay and upregulating SMAD3.
    Yang L; Chen Y; Liu N; Lu Y; Ma W; Yang Z; Gan W; Li D
    Mol Cancer; 2022 Jan; 21(1):23. PubMed ID: 35042525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma.
    Chen Y; Yang L; Liu N; Shi Q; Yin X; Han X; Gan W; Li D
    Curr Cancer Drug Targets; 2021; 21(8):713-723. PubMed ID: 33845743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The positive regulation loop between NRF1 and NONO-TFE3 fusion promotes phase separation and aggregation of NONO-TFE3 in NONO-TFE3 tRCC.
    Wang B; Gan W; Han X; Liu N; Ma T; Li D
    Int J Biol Macromol; 2021 Apr; 176():437-447. PubMed ID: 33592266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
    Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
    Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma.
    Chen Y; Yang L; Lu Y; Liu N; Ma W; Fan H; Hu Q; Han X; Gan W; Li D
    Cancer Lett; 2022 Jul; 538():215689. PubMed ID: 35447281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
    Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
    J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estradiol increases risk of topoisomerase IIβ-mediated DNA strand breaks to initiate Xp11.2 translocation renal cell carcinoma.
    Shi Q; Liu N; Yang L; Chen Y; Lu Y; Guo H; Han X; Li D; Gan W
    Cell Commun Signal; 2021 Nov; 19(1):114. PubMed ID: 34784933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
    Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
    Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA like NMRK2 mRNA functions as a key molecular scaffold to enhance mitochondrial respiration of NONO-TFE3 rearranged renal cell carcinoma in an NAD
    Chen Y; Lu Y; Yang L; Ma W; Dong Y; Zhou S; Liu N; Gan W; Li D
    J Exp Clin Cancer Res; 2023 Sep; 42(1):252. PubMed ID: 37770905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
    Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
    Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction to: Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
    Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
    J Hematol Oncol; 2021 Sep; 14(1):144. PubMed ID: 34521439
    [No Abstract]   [Full Text] [Related]  

  • 14. The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma.
    Liu N; Guo W; Shi Q; Zhuang W; Pu X; Chen S; Qu F; Xu L; Zhao X; Li X; Zhang G; Guo H; Gan W; Li D
    Sci Rep; 2020 Oct; 10(1):16361. PubMed ID: 33004995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma.
    Wang B; Yin X; Gan W; Pan F; Li S; Xiang Z; Han X; Li D
    Autophagy; 2021 Sep; 17(9):2475-2493. PubMed ID: 33019842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
    Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
    Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
    Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
    Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
    Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
    BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers.
    Park JS; Lee ME; Jang WS; Kim J; Park SM; Ham WS
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
    Pflueger D; Sboner A; Storz M; Roth J; Compérat E; Bruder E; Rubin MA; Schraml P; Moch H
    Neoplasia; 2013 Nov; 15(11):1231-40. PubMed ID: 24339735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.